GeoVax Expands Scientific Advisory Board with Global Vaccine Experts to Advance Biothreat and Vulnerable Population Protection
TL;DR
GeoVax strengthens its competitive edge by adding top vaccine and immunology experts to its advisory board, accelerating development of vaccines for underserved populations and cancers.
GeoVax expanded its Scientific Advisory Board with experts in vaccine design, T-cell immunology, viral pathogenesis, and immunocompromised medicine to guide its MVA platform and clinical strategy.
GeoVax's enhanced advisory board focuses on developing vaccines that protect vulnerable populations in low-income countries and immunocompromised patients, aiming for more equitable global health outcomes.
GeoVax assembled a dream team of vaccine experts including Oxford's Teresa Lambe and T-cell mapping pioneer Alessandro Sette to tackle infectious diseases and cancers.
Found this article helpful?
Share it with your network and spread the knowledge!
GeoVax Labs, Inc. announced a strategic expansion of its Scientific Advisory Board with the appointment of four internationally recognized experts in vaccine design, T-cell immunology, viral pathogenesis, and immunocompromised-host medicine. This move is designed to support the company's current and future development efforts with its multi-antigen MVA vector platform for vaccines targeting biothreat pathogens and vulnerable populations. The newly appointed members join Prof. Teresa Lambe, whose appointment was previously announced, forming a comprehensive advisory team to guide the company's scientific direction.
Dr. Alessandro Sette, an authority in T-cell epitope mapping and immune correlates of protection, leads the NIH Immune Epitope Database and is recognized for defining T-cell immunity across SARS-CoV-2, Mpox, and Ebola. Prof. Lance Turtle, a clinician-scientist specializing in viral pathogenesis and post-infection immune recovery, provides key translational insights into long-term immunity and emerging pathogen preparedness. Prof. Thushan I. de Silva, an expert in human viral immunology and vaccine responses, leads studies across Europe, Asia, and Africa evaluating population-level vaccine immunity and viral evolution. Dr. Joshua A. Hill, a leading infectious-disease expert focusing on vaccine response in immunocompromised and transplant patients, aligns with GeoVax's emphasis on protecting high-risk, underserved populations.
David Dodd, GeoVax Chairman & CEO, stated that assembling this exceptional team strengthens GeoVax's position at the forefront of vaccine innovation. Their combined experience from antigen design to human immunology and clinical translation aligns with the company's mission to deliver durable, broad-spectrum protection to both global and immunocompromised populations. Dr. Kelly McKee, Chief Medical Officer, added that the addition of these experts ensures clinical strategy is guided by cutting-edge immunology insight and global research expertise. Their collaboration will be instrumental as GeoVax advances vaccines and immunotherapies designed to protect those who remain most vulnerable, particularly those in low and middle income countries and immunocompromised patients underserved by traditional approaches.
Dr. Mark Newman, Chief Scientific Officer, stated that this expanded SAB strengthens multiple aspects of the company's R&D platform. With direct input from respected scientific leaders, GeoVax can ensure vaccine and immunotherapy candidates deliver real-world impact. The company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as a primary vaccine for immunocompromised patients and as a booster vaccine. For more information about clinical trials and updates, visit https://www.geovax.com.
Curated from NewMediaWire
